

## DAFTAR PUSTAKA

- Abdullah A, Wolfe R, Stoelwinder JU, de Courten M, Stevenson C, Walls HL, Peeters A. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. *Int J Epidemiol*. 2011 Aug;40(4):985-96. doi: 10.1093/ije/dyr018. Epub 2011 Feb 27. PMID: 21357186.
- Abdullah A, Wolfe R, Stoelwinder JU, Stevenson C, Walls HL, Peeters A. The impact of obesity level and obesity duration on cardiovascular disease risk. *Public Health Nutrition*. 2014;17(4):846–854. doi:10.1017/S1368980013000888
- Ala-Korpela M. The culprit is the carrier, not the loads: cholesterol, triglycerides and apolipoprotein B in atherosclerosis and coronary heart disease. *Int J Epidemiol* 2019;48(5):1389–92.
- Alderman MH. Hyperuricemia and cardiovascular risk. *Curr Opin Nephrol Hypertens*. 2002;11(3):337–341.
- Amani-Beni R, Darouei B, Zefreh H, Sheikhabaehi E, Sadeghi M. Effect of Obesity Duration and BMI Trajectories on Cardiovascular Disease: A Narrative Review. *Cardiol Ther*. 2023 Jun;12(2):307-326. doi: 10.1007/s40119-023-00317-6. Epub 2023 May 8. PMID: 37154885; PMCID: PMC10209362.
- American College of Cardiology. ASCVD risk estimator Plus. Available at: [https:// tools.acc.org/ASCVD-Risk-Estimator-Plus](https://tools.acc.org/ASCVD-Risk-Estimator-Plus). Accessed October 3, 2024.
- Andersson EM, Liv P, Nordin S, Näslund U, Lindvall K. Does a multi-component intervention including pictorial risk communication about subclinical atherosclerosis improve perceptions of cardiovascular disease risk without deteriorating efficacy beliefs? *Soc Sci Med*. 2024 Jan;341:116530. doi: 10.1016/j.socscimed.2023.116530. Epub 2023 Dec 24. PMID: 38169179.
- Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. *Ann Rheum Dis*. 2008 Jul;67(7):960-6. doi: 10.1136/ard.2007.076232. Epub 2007 Nov 2. PMID: 17981913; PMCID: PMC2564789.
- Attiq A, Afzal S, Ahmad W, Kandeel M. Hegemony of inflammation in atherosclerosis and coronary artery disease. *Eur J Pharmacol*. 2024 Mar 5;966:176338. doi: 10.1016/j.ejphar.2024.176338. Epub 2024 Jan 17. PMID: 38242225.
- Bahadoran, Z., Mirmiran, P., Kashfi, K., & Ghasemi, A. (2021). Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection. *Pflügers*

Archiv - *European Journal of Physiology*. 474. 10.1007/s00424-021-02606-2.

Bedir A, Topbas M, Tanyeri F, Alvur M, Arik N. Leptin might be a regulator of serum uric acid concentration in human. *Jpn Heart J* 2003;44:527-36.

Bigehe A, Shekar C, Gulati M. Sex differences in coronary artery calcium and longterm CV mortality. *Curr Cardiol Rep* 2020;22(4):21.

Bonora E, Targher G, Zenere M.B, Saggiani F, Cacciatori V, Tosi, F, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. *Int J Obes Relat Metab Disord* 1996;20:975-80.

Braga F, Pasqualetti S, Ferraro S, Panteghini M. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. *Clin Chem Lab Med*. 2016 Jan;54(1):7-15. doi: 10.1515/cclm-2015-0523. PMID: 26351943.

Castoldi A, Naffah de Souza C, Câmara NO, Moraes-Vieira PM. The Macrophage Switch in Obesity Development. *Front Immunol*. 2016 Jan 5;6:637. doi: 10.3389/fimmu.2015.00637. PMID: 26779183; PMCID: PMC4700258.

Chang CC, Wu CH, Liu LK, Chou RH, Kuo CS, Huang PH, Chen LK, Lin SJ. Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan Longitudinal Aging Study. *Sci Rep*. 2018 Mar 27;8(1):5234. doi: 10.1038/s41598-018-22997-0. PMID: 29588485; PMCID: PMC5869680.

Chen C, Lü JM, Yao Q. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. *Med Sci Monit*. 2016 Jul 17;22:2501-12. doi: 10.12659/msm.899852. PMID: 27423335; PMCID: PMC4961276.

Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. *J Zhejiang Univ Sci B* 2007;8:593-8.

Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. *Am J Med*. 2007 May;120(5):442-7. doi: 10.1016/j.amjmed.2006.06.040. PMID: 17466656.

Csige I, Ujvárosy D, Szabó Z, Lőrincz I, Paragh G, Harangi M, et al. The Impact of Obesity on the Cardiovascular System. *J Diabetes Res*. 2018 Nov 4;2018:3407306. doi: 10.1155/2018/3407306.

Dahlan MS. *Besar sampel dalam penelitian kedokteran dan kesehatan*. 2014. Edisi 3, Salemba Medika, Jakarta.

- Davidson KW, Mangione CM, Barry MJ, Nicholson WK, Cabana MD, Caughey AB, et al. Collaboration and Shared Decision-Making Between Patients and Clinicians in Preventive Health Care Decisions and US Preventive Services Task Force Recommendations. *JAMA*. 2022 Mar 22;327(12):1171-1176. doi: 10.1001/jama.2022.3267. PMID: 35315879.
- Derr JN., Black, A, *Atherosclerotic Cardiovascular Disease, Epidemiology, Pathophysiology, and Practical Risk Assessment*, Elsevier, 2024
- Després, J.P. Body fat distribution and risk of cardiovascular disease: an update. *Circulation* .2012, 126(10), 1301–1313.
- Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. *Endocr Rev* 2019;40(6):1447–67.
- Doodnauth SA, Grinstein S, Maxson ME. Constitutive and stimulated macropinocytosis in macrophages: roles in immunity and in the pathogenesis of atherosclerosis. *Philos Trans R Soc Lond Ser B Biol Sci* 2019;374(1765):20180147.
- Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. *Sig Transduct Target Ther* 9, 212 (2024). <https://doi.org/10.1038/s41392-024-01916-y>
- Dwiputra Bambang, Desandri Dwita Rian, Hartopo Anggoro Budi, Juzar Dafsah Arifa, Alkatiri Amir Aziz, Zuhdi Naufal, et al. Risk estimation for recurrent cardiovascular events using the SMART-REACH model and direct inpatient cost profiling in Indonesian ASCVD patients: a large-scale multicenter study. *Frontiers in Cardiovascular Medicine*. Vol 11, 2024
- Edwards NL. The role of hyperuricemia in vascular disorders. *Curr Opin Rheumatol*.2009 Mar;21(2):132-7. doi: 10.1097/BOR.0b013e3283257b96. Erratum in: *Curr Opin Rheumatol*. 2010 Jan;22(1):107. PMID: 19339923.
- Emerging Risk Factors Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *The Lancet*. 2009;373(9669):1083–1096. doi:10.1016/S0140-6736(09)60318-4 Ferhatbegovic L, Mrsic D, Kusljugic S, Pojskic B. LDL-C: the only causal risk factor for ASCVD. Why is it still overlooked and underestimated? *Curr Atheroscler Rep* 2022;24(8):635–42.
- Framingham Heart Study. Available at: <https://www.framinghamheartstudy.org/>. Accessed October 14, 2024.
- Fruehwald-Schultes B, Peters A, Kern W, Beyer J, Pfutzner A. Serum leptin is associated with serum uric acid concentrations in humans. *Metabolism* 1999;48: 677-80.

- Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science*. 2005 Jan 21;307(5708):426-30.
- Gil-Campos M, Aguilera CM, Cañete R, Gil A. Uric acid is associated with features of insulin resistance syndrome in obese children at prepubertal stage. *Nutr Hosp*. 2009 Sep-Oct;24(5):607-13. PMID: 19893872.
- Gkrinia, E.M.M.; Belančić, A. The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review. *Curr. Issues Mol. Biol*. 2025, 47, 357. <https://doi.org/10.3390/cimb47050357>
- Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014 Jun 24;129(25 Suppl 2):S49-73. doi: 10.1161/01.cir.0000437741.48606.98. Epub 2013 Nov 12. Erratum in: *Circulation*. 2014 Jun 24;129(25 Suppl 2):S74-5. PMID: 24222018.
- Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. *Nutr Metab (Lond)*. 2004 Oct 19;1(1):10. doi: 10.1186/1743-7075-1-10. PMID: 15507132; PMCID: PMC529248.
- Hisatome I, Ichida K, Mineo I, Ohtahara A, Ogino K, Kuwabara M, et al. Japanese Society of Gout and Uric & Nucleic Acids. 2019 Guidelines for Management of Hyperuricemia and Gout 3rd Edition. *Gout Uric Nucleic Acids* 2020, 44 (Supplement), 1–40
- Indonesian Society of Hypertension (InaSH), 2021, Konsensus Penatalaksanaan hipertensi 2021: Update Konsensus Perhimpunan Dokter Hipertensi Indonesia 2019, PERHI.
- Joosten LAB, Crişan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. *Nat Rev Rheumatol*. 2020 Feb;16(2):75-86. doi: 10.1038/s41584-019-0334-3. Epub 2019 Dec 10. PMID: 31822862; PMCID: PMC7075706.
- Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. *World Rev Nutr Diet* 2005;94:1–12
- Khanna D, Welch BS, Rehman A. Pathophysiology of Obesity. [Updated 2022 Oct 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;2025Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK572076/>

- Khan SS, Ning H, Wilkins JT, Allen NB, Carnethon MR, Berry JD, et al. Association of weight gain in young adulthood with risk of coronary artery calcification later in life. *JAMA*. 2014;312(12):1235–1244. doi:10.1001/jama.2014.8842
- Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The Role of Adipokines in Inflammatory Mechanisms of Obesity. *Int J Mol Sci*. 2022 Nov 29;23(23):14982. doi: 10.3390/ijms232314982. PMID: 36499312; PMCID: PMC9740598.
- Kuwabara, M., Kodama, T., Ae, R., Kanbay, M., Hernando, AA., Borghi, C., et al. Update in uric acid, hypertension, and cardiovascular diseases. *Hypertens Res* 46, 1714–1726 (2023).
- Lee MJ, Khang AR, Kang YH, Yun MS, Yi D. Synergistic Interaction between Hyperuricemia and Abdominal Obesity as a Risk Factor for Metabolic Syndrome Components in Korean Population. *Diabetes Metab J*. 2022;46(5):756-766.
- Lee, S.J., Oh, B.K. & Sung, KC. Uric acid and cardiometabolic diseases. *Clin Hypertens* 26, 13 (2020). <https://doi.org/10.1186/s40885-020-00146-y>
- Libby P. Inflammation in atherosclerosis. *Nature*. 2002 Dec 19-26;420(6917):868-74. doi: 10.1038/nature01323. PMID: 12490960.
- Li K, Li K, Yao Q, Shui X, Zheng J, He Y, Lei W. The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor. *Heliyon*. 2023 May 9;9(5):e16097. doi: 10.1016/j.heliyon.2023.e16097. PMID: 37215840; PMCID: PMC10199191.
- Li, L., Zhang, Y. & Zeng, C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. *Am. J. Transl. Res.* 12, 3167–3181 (2020).
- Li M, Hu X, Fan Y, Li K, Zhang X, Hou W, Tang Z. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. *Sci Rep*. 2016 Jan 27;6:19520. doi: 10.1038/srep19520. PMID: 26814153; PMCID: PMC4728388.
- Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS, Virani SS, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American college of cardiology. *Circulation* (New York, N.Y.) 2019;139:e1162–77.
- Lopez-Jimenez F, Almahmeed W, Bays H, Cuevas A, Di Angelantonio E, le Roux CW, Sattar N, Sun MC, Wittert G, Pinto FJ, Wilding JPH. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity

- Federation. *Eur J Prev Cardiol.* 2022 Dec 7;29(17):2218-2237. doi: 10.1093/eurjpc/zwac187. PMID: 36007112.
- Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. *Annu Rev Physiol.* 2015;77:323-45. doi: 10.1146/annurev-physiol-021113-170343. Epub 2014 Nov 12. PMID: 25422986.
- Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. *Metabolism* 1998;47:929-33.
- Mongraw-Chaffin M, Foster MC, Kalyani RR, Vaidya D, Burke GL, Woodward M, Anderson CA. Obesity Severity and Duration Are Associated With Incident Metabolic Syndrome: Evidence Against Metabolically Healthy Obesity From the Multi-Ethnic Study of Atherosclerosis. *J Clin Endocrinol Metab.* 2016 Nov;101(11):4117-4124. doi: 10.1210/jc.2016-2460. Epub 2016 Aug 23. PMID: 27552544; PMCID: PMC5095229.
- Ndrepepa G. Uric acid and cardiovascular disease. *Clin Chim Acta.* 2018;484:150–163.
- Nielsen Hs, Torp-Pedersen C, Finer N, Caterson ID, Van Gaal L, James WP, Maggioni AP, Sharma AM, Coutinho W, Andersson C. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. *PLoS One.* 2013;8(3):e59121. doi: 10.1371/journal.pone.0059121. Epub 2013 Mar 22. PMID: 23533601; PMCID: PMC3606441.
- Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. *BMJ Glob Health.* 2022 Sep;7(9):e009773. doi: 10.1136/bmjgh-2022-009773. PMID: 36130777; PMCID: PMC9494015.
- Pahwa R, Ishwarlal J. Atherosclerosis. *StatPearls.* 2023. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK507799/>. Accessed October 30, 2024.
- Perhimpunan Reumatologi Indonesia. Pedoman Diagnosis dan Tatalaksana Hiperurisemia & Arthritis Gout, 2024.
- Perkeni, Panduan Pengelolaan Dislipidemia di Indonesia, 2021
- Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the

- American Heart Association. *Circulation*. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22.
- Prasad, M., Matteson, E. L., Herrmann, J., Gulati, R., Rihal, C. S., Lerman, L. O., et al. (2017). Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women. *Hypertension* 69 (2), 236–242. doi: 10.1161/HYPERTENSIONAHA.116.08436
- Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. [Updated 2023 May 4]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279167/>
- Reis JP, Allen NB, Gunderson EP, Lee JM, Lewis CE, Loria CM, et al. Duration of obesity and risk of developing subclinical atherosclerosis: The CARDIA Study. *Journal of the American College of Cardiology*. 2013;62(17):1564–1572. doi:10.1016/j.jacc.2013.07.021
- Riskedas, Riset Kesehatan Dasar 2018
- Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. *J Am Coll Cardiol* 2020;76:2982–3021.
- Rubin JB, Borden WB. Coronary heart disease in young adults. *Curr Atheroscler Rep* 2012;14(2):140–9.
- Shi Y, Hou W, Jiang T, Zhang J, Li X, Liu M, et al. Uric acid metabolism and vascular complications in obesity and diabetes. *Front Endocrinol*. 2021;12:729742.
- Skoczyńska M, Chowaniec M, Szymczak A, Langner-Hetmańczuk A, Maciążek-Chyra B, Wiland P. Pathophysiology of hyperuricemia and its clinical significance - a narrative review. *Reumatologia*. 2020;58(5):312-323. doi: 10.5114/reum.2020.100140. Epub 2020 Oct 29. PMID: 33227090; PMCID: PMC7667948.
- Song J, Jin C, Shan Z, Teng W, Li J. Prevalence and Risk Factors of Hyperuricemia and Gout: A Cross-sectional Survey from 31 Provinces in Mainland China. *J Transl Int Med*. 2022 Jul 7;10(2):134-145. doi: 10.2478/jtim-2022-0031. PMID: 35959454; PMCID: PMC9328039.
- Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. *Sci Rep*. 2018 Mar 12;8(1):4314. doi: 10.1038/s41598-018-22570-9. PMID: 29531237; PMCID: PMC5847518.

- Stone NJ, Smith SC Jr, Orringer CE, Rigotti NA, Navar AM, Khan SS, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2022 Mar 1;79(8):819-836. doi: 10.1016/j.jacc.2021.12.016. PMID: 35210038.
- Summerhill VI, Grechko AV, Yet SF, Sobenin IA, Orekhov AN. The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. *Int J Mol Sci*. 2019 Jul 20;20(14):3561. doi: 10.3390/ijms20143561. PMID: 31330845; PMCID: PMC6678182.
- Tian T, Wang Y, Xie W, Zhang J, Zhu Q, Peng X, et al. Association of Serum Uric Acid with Clustering of Cardiovascular Risk Factors and a 10-Year Atherosclerotic Cardiovascular Disease Risk Score in Jiangsu Adults, China
- Vrablik M, Corsini A, Tumova E. Beta-blockers for atherosclerosis prevention: a missed opportunity? *Curr Atheroscler Rep* 2022;24(3):161–9.
- Wajchenberg B, Nery M, Cunha M, Silva MER da. *Adipose tissue at the crossroads in the development of the metabolic syndrome, inflammation and atherosclerosis*. *Arq Bras Endocrinol Metabol*. 2009;53(2):145–150.
- Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of cardiovascular mortality: a systematic review and meta-analysis of prospective cohort studies. *Atherosclerosis*. 2016;245:31–38.
- Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis
- Wojtasińska A, Frąk W, Lisińska W, Sapeda N, Młynarska E, Rysz J, et al. Novel Insights into the Molecular Mechanisms of Atherosclerosis. *Int J Mol Sci*. 2023 Aug 30;24(17):13434. doi: 10.3390/ijms241713434. PMID: 37686238; PMCID: PMC10487483.
- Wong ND, Budoff MJ, Ferdinand K, Graham IM, Michos ED, Reddy T, Shapiro MD, Toth PP. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. *Am J Prev Cardiol*. 2022 Mar 15;10:100335. doi: 10.1016/j.ajpc.2022.100335. PMID: 35342890; PMCID: PMC8943256.
- World Health Organization. Obesity: preventing and managing the global epidemic. WHO Technical Report Series No. 894. 2000.
- World Health Organization, 1 March 2024, Obesity and Overweight.
- Yadav D, Lee ES, Kim HM, Lee EY, Choi E, Chung CH. Hyperuricemia as a Potential Determinant of Metabolic Syndrome. *J Lifestyle Med*. 2013 Sep;3(2):98-106. Epub 2013 Sep 30. PMID: 26064845; PMCID: PMC4390742.

- Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. *Int J Mol Sci.* 2021 Aug 26;22(17):9221. doi: 10.3390/ijms22179221. PMID: 34502127; PMCID: PMC8431537.
- Yu W, Xie D, Yamamoto T, Koyama H, Cheng J. Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond. *Rev Endocr Metab Disord.* 2023 Apr;24(2):327-343. doi: 10.1007/s11154-023-09787-4. Epub 2023 Jan 30. PMID: 36715824.
- Yu W, Cheng JD. Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. *Front Pharmacol.* 2020 Nov 16;11:582680. doi: 10.3389/fphar.2020.582680. PMID: 33304270; PMCID: PMC7701250.
- Zhuang Y, Huang H, Hu X, Zhang J, Cai Q. Serum uric acid and diabetic peripheral neuropathy: a double-edged sword. *Acta Neurol Belg.* 2023 Jun;123(3):857-863. doi: 10.1007/s13760-022-01978-1. Epub 2022 May 29. PMID: 35643885; PMCID: PMC10238292.